Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia

SIMPLE SUMMARY: Nearly 30% of adult acute myeloid leukemias (AML) harbor mutations of the nucleophosmin (NPM1) gene. These forms have a favorable outcome but, despite notable treatment advances, about 50% of patients still die of progressive disease. Thus, identification of new therapeutic opportuni...

Descripción completa

Detalles Bibliográficos
Autores principales: De Cicco, Marica, Lagreca, Ivana, Basso, Sabrina, Barozzi, Patrizia, Muscianisi, Stella, Bianco, Alba, Riva, Giovanni, Di Vincenzo, Sara, Pulvirenti, Chiara, Sapuppo, Davide, Siciliano, Mariangela, Rosti, Vittorio, Candoni, Anna, Zecca, Marco, Forghieri, Fabio, Luppi, Mario, Comoli, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216567/
https://www.ncbi.nlm.nih.gov/pubmed/37345068
http://dx.doi.org/10.3390/cancers15102731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216567/
https://www.ncbi.nlm.nih.gov/pubmed/37345068
http://dx.doi.org/10.3390/cancers15102731

Ejemplares similares